European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations.
Adolescent
Anti-Infective Agents
/ therapeutic use
Anti-Inflammatory Agents
/ therapeutic use
Antipruritics
/ therapeutic use
Biological Products
/ therapeutic use
Child
Dermatitis, Atopic
/ drug therapy
Dermatologic Agents
/ therapeutic use
Eczema
/ drug therapy
Emollients
/ therapeutic use
Female
Humans
Janus Kinases
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
17
02
2022
accepted:
03
06
2022
pubmed:
4
9
2022
medline:
15
10
2022
entrez:
3
9
2022
Statut:
ppublish
Résumé
The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This second part of the guideline includes recommendations and detailed information on basic therapy with emollients and moisturizers, topical anti-inflammatory treatment, antimicrobial and antipruritic treatment and UV phototherapy. Furthermore, this part of the guideline covers techniques for avoiding provocation factors, as well as dietary interventions, immunotherapy, complementary medicine and educational interventions for patients with atopic eczema and deals with occupational and psychodermatological aspects of the disease. It also contains guidance on treatment for paediatric and adolescent patients and pregnant or breastfeeding women, as well as considerations for patients who want to have a child. A chapter on the patient perspective is also provided. The first part of the guideline, published separately, contains recommendations and guidance on systemic treatment with conventional immunosuppressive drugs, biologics and janus kinase (JAK) inhibitors, as well as information on the scope and purpose of the guideline, and a section on guideline methodology.
Substances chimiques
Anti-Infective Agents
0
Anti-Inflammatory Agents
0
Antipruritics
0
Biological Products
0
Dermatologic Agents
0
Emollients
0
Janus Kinases
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1904-1926Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Loden M, Andersson AC, Anderson C et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol 2002; 82: 45-47.
Darsow U, Lübbe J, Taïeb A et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-295.
Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682.
van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev 2017; 2: CD012119.
Boralevi F, Saint Aroman M, Delarue A et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol 2014; 28: 1456-1462.
Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99-106.
Akerstrom U, Reitamo S, Langeland T et al. Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial. Acta Derm Venereol 2015; 95: 587-592.
Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol 2009; 26: 273-278.
Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. J Eur Acad Dermatol Venereol 2015; 29: 1071-1081.
Mengeaud V, Phulpin C, Bacquey A, Boralevi F, Schmitt AM, Taieb A. An innovative oat-based sterile emollient cream in the maintenance therapy of childhood atopic dermatitis. Pediatr Dermatol 2015; 32: 208-215.
Angelova-Fischer I, Rippke F, Richter D et al. Stand-alone emollient treatment reduces flares after discontinuation of topical steroid treatment in atopic dermatitis: a double-blind, randomized, vehicle-controlled, Left-right Comparison Study. Acta Derm Venereol 2018; 98: 517-523.
Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 351-368.
Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.
Gelmetti C, Wollenberg A. Atopic dermatitis - all you can do from the outside. Br J Dermatol 2014; 170(Suppl 1): 19-24.
National Institute for Health and Care Excellence. NICE pathways: eczema. Vol. 03.08.2021. 2020.
Mandeau A, Aries MF, Boe JF et al. Rhealba(R) oat plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune inflammatory mediators. Planta Med 2011; 77: 900-906.
Gueniche A, Knaudt B, Schuck E et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008; 159: 1357-1363.
Aries MF, Hernandez-Pigeon H, Vaissiere C et al. Anti-inflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models. Clin Cosmet Investig Dermatol 2016; 9: 421-434.
Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. Cochrane Database Syst Rev 2013; 2013: Cd004416.
Gehring W, Bopp R, Rippke F, Gloor M. Effect of topically applied evening primrose oil on epidermal barrier function in atopic dermatitis as a function of vehicle. Arzneimittelforschung 1999; 49: 635-642.
Simpson EL, Chalmers JR, Hanifin JM et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014; 134: 818-823.
Horimukai K, Morita K, Narita M et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 2014; 134: 824, e6-830.
Chalmers JR, Haines RH, Bradshaw LE et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet 2020; 395: 962-972.
Skjerven HO, Rehbinder EM, Vettukattil R et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 2020; 395: 951-961.
Uehara M, Takada K. Use of soap in the management of atopic dermatitis. Clin Exp Dermatol 1985; 10: 419-425.
Blume-Peytavi U, Cork MJ, Faergemann J, Szczapa J, Vanaclocha F, Gelmetti C. Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. J Eur Acad Dermatol Venereol 2009; 23: 751-759.
Koutroulis I, Pyle T, Kopylov D, Little A, Gaughan J, Kratimenos P. The association between bathing habits and severity of atopic dermatitis in children. Clin Pediatr (Phila) 2016; 55: 176-181.
Denda M, Sokabe T, Fukumi-Tominaga T, Tominaga M. Effects of skin surface temperature on epidermal permeability barrier homeostasis. J Invest Dermatol 2007; 127: 654-659.
Hua T, Yousaf M, Gwillim E et al. Does daily bathing or showering worsen atopic dermatitis severity? A systematic review and meta-analysis. Arch Dermatol Res 2020; 313: 729-735.
Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol 2012; 26: 1176-1193.
Koutroulis I, Petrova K, Kratimenos P, Gaughan J. Frequency of bathing in the management of atopic dermatitis: to bathe or not to bathe? Clin Pediatr (Phila) 2014; 53: 677-681.
Ring J, Mohrenschlager M. Allergy to peanut oil--clinically relevant? J Eur Acad Dermatol Venereol 2007; 21: 452-455.
Santer M, Ridd MJ, Francis NA et al. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. BMJ 2018; 361: k1332.
Maarouf M, Hendricks AJ, Shi VY. Bathing additives for atopic dermatitis - a systematic review. Dermatitis 2019; 30: 191-197.
Ludwig G. On the topical effect of sea water tub-baths with and without addition of an oil emulsion. Zeitschrift fur Haut-und Geschlechtskrankheiten 1968; 43: 683-688.
Dittmar HC, Pflieger D, Schempp CM, Schopf E, Simon JC. Comparison of balneophototherapy and UVA/B mono-phototherapy in patients with subacute atopic dermatitis. Hautarzt 1999; 50: 649-653.
Wollenberg A, Oranje A, Deleuran M et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30: 729-747.
Wollenberg A, Frank R, Kroth J et al. Proactive therapy of atopic eczema - an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 2009: 117-121.
Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Annals Dermatol 2012; 24: 253-260.
Schnopp C, Holtmann C, Stock S et al. Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial. Dermatology 2002; 204: 56-59.
Gonzalez-Lopez G, Ceballos-Rodriguez RM, Gonzalez-Lopez JJ, Feito Rodriguez M, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2016; 177: 688-695.
Kohn LL, Kang Y, Antaya RJ. A randomized, controlled trial comparing topical steroid application to wet versus dry skin in children with atopic dermatitis (AD). J Am Acad Dermatol 2016; 75: 306-311.
Janmohamed SR, Oranje AP, Devillers AC et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2014; 70: 1076-1082.
Cadmus SD, Sebastian KR, Warren D et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split-body control study. Pediatr Dermatol 2019; 36: 437-441.
Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528-537.
Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367-1360.
Niedner R. Therapie mit systemischen Glukokortikoiden. Hautarzt 2001; 52: 1062-1071.
Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf 2015; 38: 493-509.
Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands adult atopic DermatitisStudy group. Br J Dermatol 1999; 140: 1114-1121.
Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984; 1: 246-253.
Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003; 21: 193-200.
Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. J Dermatolog Treat 2010; 21: 157-166.
Stalder JF, Aubert H, Anthoine E et al. Topical corticosteroid phobia in atopic dermatitis: international feasibility study of the TOPICOP score. Allergy 2017; 72: 1713-1719.
Aubert-Wastiaux H, Moret L, Le Rhun A et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011; 165: 808-814.
Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Annals Dermatol 2015; 27: 499-506.
Müller SM, Tomaschett D, Euler S, Vogt DR, Herzog L, Itin P. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology 2016; 232: 444-452.
Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013; 15: 303-310.
Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005; 53: S17-S25.
Ruzicka T, Bieber T, Schöpf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-821.
Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-809.
Reitamo S, Wollenberg A, Schopf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European tacrolimus ointment study group. Arch Dermatol 2000; 136: 999-1006.
Meurer M, Folster-Holst R, Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-277.
Reitamo S, Van Leent EJ, Ho V et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-546.
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev 2015: CD009864.
Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2010; 21: 144-156.
Wollenberg A, Reitamo S, Atzori F et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742-750.
Thaci D, Reitamo S, Gonzalez Ensenat MA et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-1356.
Ho VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-162.
Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139: 1184-1186.
Reitamo S, Mandelin J, Rubins A et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol 2009; 48: 348-355.
Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy Dermatologii i Alergologii 2019; 36: 752-759.
Reitamo S, Rustin M, Harper J et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942-951.
Sigurgeirsson B, Boznanski A, Todd G et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015; 135: 597-606.
Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-513.
Hong CH, Gooderham M, Bissonnette R. Evidence review of topical Calcineurin inhibitors for the treatment of adult atopic dermatitis. J Cutan Med Surg 2019; 23: 5s-10s.
Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. J Dermatol 2018; 45: 936-942.
Paller AS, Fölster-Holst R, Chen SC et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol 2020; 83: 375-381.
Ring J, Barker J, Behrendt H et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European dermatology forum. J Eur Acad Dermatol Venereol 2005; 19: 663-671.
Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-295.
Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52-56.
Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association between malignancy and topical use of Pimecrolimus. JAMA Dermatol 2015; 151: 594-599.
Deleuran M, Vestergaard C, Vølund A, Thestrup-Pedersen K. Topical Calcineurin inhibitors, topical glucocorticoids and cancer in children: a Nationwide study. Acta Derm Venereol 2016; 96: 834-835.
Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association between topical Calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol 2020; 156: 1066-1073.
Castellsague J, Kuiper JG, Pottegard A et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (joint European longitudinal lymphoma and skin cancer evaluation - JOELLE study). Clin Epidemiol 2018; 10: 299-310.
Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. J Dtsch Dermatol Ges 2012; 10: 167-172.
Vestergaard C, Wollenberg A, Barbarot S et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol 2019; 33: 1644-1659.
Bissonnette R, Papp KA, Poulin Y et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175: 902-911.
Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol 2018; 178: 424-432.
Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 2020; 145: 572-582.
Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 687-695.
Alexander H, Paller AS, Traidl-Hoffmann C et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the international eczema council skin infection group. Br J Dermatol 2020; 182: 1331-1342.
Cornelissen C, Marquardt Y, Czaja K et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 2012; 129: 33.e1-33.e8.
Schlievert PM, Case LC, Strandberg KL, Abrams BB, Leung DYM. Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis. Clin Infect Dis 2008; 46: 1562-1567.
Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49: 198-205.
Seegräber M, Worm M, Werfel T et al. Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol 2020; 34: 1074-1079.
Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol 2016; 51: 329-337.
Kreth HW, Hoeger PH. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur J Pediatr 2006; 165: 677-683.
Schneider L, Weinberg A, Boguniewicz M et al. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. J Allergy Clin Immunol 2010; 126: 1306-7.e2.
Osier E, Eichenfield L. The utility of Cantharidin for the treatment of Molluscum Contagiosum. Pediatr Dermatol 2015; 32: 295-296.
Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112: 667-674.
Mathes EF, Oza V, Frieden IJ et al. "Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak. Pediatrics 2013; 132: e149-e157.
Neri I, Dondi A, Wollenberg A et al. Atypical forms of hand, foot, and mouth disease: a prospective study of 47 Italian children. Pediatr Dermatol 2016; 33: 429-437.
Lynch MD, Sears A, Cookson H et al. Disseminated coxsackievirus A6 affecting children with atopic dermatitis. Clin Exp Dermatol 2015; 40: 525-528.
Johnson VK, Hayman JL, McCarthy CA, Cardona ID. Successful treatment of eczema coxsackium with wet wrap therapy and low-dose topical corticosteroid. J Allergy Clin Immunol Pract 2014; 2: 803-804.
Sparber F, De Gregorio C, Steckholzer S et al. The skin commensal yeast Malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation. Cell Host Microbe 2019; 25: 389-403.e6.
Thammahong A, Kiatsurayanon C, Edwards SW, Rerknimitr P, Chiewchengchol D. The clinical significance of fungi in atopic dermatitis. Int J Dermatol 2020; 59: 926-935.
Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The role of Malassezia spp. in atopic dermatitis. J Clin Med 2015; 4: 1217-1228.
Svejgaard E, Larsen PO, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. J Eur Acad Dermatol Venereol 2004; 18: 445-449.
Kamata Y, Tominaga M, Takamori K. Itch in atopic dermatitis management. Curr Probl Dermatol 2016; 50: 86-93.
Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB Jr. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol 2012; 92: 455-461.
Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.
Silverberg JI, Yosipovitch G, Simpson EL et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol 2020; 82: 1328-1336.
Agache I, Song Y, Posso M et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 2021; 76: 45-58.
Worm M, Simpson EL, Thaçi D et al. Efficacy and safety of multiple Dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 131-143.
Wollenberg A, Blauvelt A, Guttman-Yassky E et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437-449.
Simpson EL, Sinclair R, Forman S et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255-266.
Simpson EL, Lacour JP, Spelman L et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.
Guttman-Yassky E, Teixeira HD, Simpson EL et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151-2168.
Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 2014; 170: 501-513.
Jaworek A, Szafraniec K, Jaworek M, Matusiak Ł, Wojas-Pelc A, Szepietowski JC. Itch relief in atopic dermatitis: comparison of narrowband ultraviolet B radiation and cyclosporine treatment. Acta Derm Venereol 2020; 100: adv00291.
Doherty V, Sylvester DG, Kennedy CT, Harvey SG, Calthrop JG, Gibson JR. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. BMJ 1989; 298: 96.
Henz BM, Metzenauer P, O'Keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. Allergy 1998; 53: 180-183.
Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy 1994; 49: 22-26.
La Rosa M, Ranno C, Musarra I, Guglielmo F, Corrias A, Bellanti JA. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994; 73: 117-122.
Wahlgren CF, Hägermark O, Bergström R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990; 122: 545-551.
Munday J, Bloomfield R, Goldman M et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 2002; 205: 40-45.
Hannuksela M, Kalimo K, Lammintausta K et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993; 70: 127-133.
Chunharas A, Wisuthsarewong W, Wananukul S, Viravan S. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. J Med Assoc Thai 2002; 85: 482-487.
Kawakami T, Kaminishi K, Soma Y, Kushimoto T, Mizoguchi M. Oral antihistamine therapy influences plasma tryptase levels in adult atopic dermatitis. J Dermatol Sci 2006; 43: 127-134.
Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019; 1: Cd012167.
Wollenberg A, Christen-Zäch S, Taieb A et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.
Church MK, Maurer M, Simons FE et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010; 65: 459-466.
Adam K, Oswald I. The hypnotic effects of an antihistamine: promethazine. Br J Clin Pharmacol 1986; 22: 715-717.
Vermeulen FM, Gerbens LAA, Schmitt J et al. The European TREatment of ATopic eczema (TREAT) registry taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema. Br J Dermatol 2020; 183: 1073-1082.
Archier E, Devaux S, Castela E et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26(Suppl 3): 22-31.
Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-a light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst 1998; 90: 1278-1284.
Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet a radiation (PUVA). The PUVA follow-up study. N Engl J Med 1997; 336: 1041-1045.
Perez HC, Benavides X, Perez JS et al. Basic aspects of the pathogenesis and prevention of non-melanoma skin cancer in solid organ transplant recipients: a review. Int J Dermatol 2017; 56: 370-378.
Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211-216.
Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042-1045.
Garritsen FM, ter Haar NM, Spuls PI. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic. Br J Dermatol 2013; 168: 688-691.
Nankervis H, Pynn EV, Boyle RJ et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev 2015; 1: Cd008426.
Fieten KB, Weststrate AC, van Zuuren EJ, Bruijnzeel-Koomen CA, Pasmans SG. Alpine climate treatment of atopic dermatitis: a systematic review. Allergy 2015; 70: 12-25.
Thorsteinsdottir S, Thyssen JP, Stokholm J, Vissing NH, Waage J, Bisgaard H. Domestic dog exposure at birth reduces the incidence of atopic dermatitis. Allergy 2016; 71: 1736-1744.
Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L. Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. J Allergy Clin Immunol 2013; 132: 616-22.e7.
Kim A, Silverberg JI. A systematic review of vigorous physical activity in eczema. Br J Dermatol 2016; 174: 660-662.
Murota H, Yamaga K, Ono E, Katayama I. Sweat in the pathogenesis of atopic dermatitis. Allergol Int 2018; 67: 455-459.
Murota H, Yamaga K, Ono E, Murayama N, Yokozeki H, Katayama I. Why does sweat lead to the development of itch in atopic dermatitis? Exp Dermatol 2019; 28: 1416-1421.
Jaros J, Wilson C, Shi VY. Fabric selection in atopic dermatitis: an evidence-based review. Am J Clin Dermatol 2020; 2: 467-482.
Lopes C, Silva D, Delgado L, Correia O, Moreira A. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol 2013; 24: 603-613.
Bao Q, Chen L, Lu Z et al. Association between eczema and risk of depression: a systematic review and meta-analysis of 188,495 participants. J Affect Disord 2018; 238: 458-464.
Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: e30.
Chan CWH, Law BMH, Liu YH et al. The association between maternal stress and childhood eczema: a systematic review. Int J Environ Res Public Health 2018; 15: 1-17.
Flanigan C, Sheikh A, DunnGalvin A, Brew BK, Almqvist C, Nwaru BI. Prenatal maternal psychosocial stress and offspring's asthma and allergic disease: a systematic review and meta-analysis. Clin Exp Allergy 2018; 48: 403-414.
Mochizuki H, Lavery MJ, Nattkemper LA et al. Impact of acute stress on itch sensation and scratching behaviour in patients with atopic dermatitis and healthy controls. Br J Dermatol 2019; 180: 821-827.
Oh SH, Bae BG, Park CO et al. Association of stress with symptoms of atopic dermatitis. Acta Derm Venereol 2010; 90: 582-588.
Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol 2016; 75: 1119-1125.e1.
Pilz AC, Schielein MC, Schuster B et al. Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry. J Eur Acad Dermatol Venereol 2022; 36: 413-421.
Tsakok T, Marrs T, Mohsin M et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol 2016; 137: 1071-1078.
Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101: E8.
Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999; 104: S114-S122.
Breuer K, Heratizadeh A, Wulf A et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 2004; 34: 817-824.
Reekers R, Busche M, Wittmann M, Kapp A, Werfel T. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. J Allergy Clin Immunol 1999; 104: 466-472.
Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. Allergy 2018; 73: 2046-2054.
Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30: 1604-1610.
Fölster-Holst R, Müller F, Schnopp N et al. Prospective, randomized controlled trial on lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155: 1256-1261.
Rosenfeldt V, Benfeldt E, Nielsen SD et al. Effect of probiotic lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111: 389-395.
Grüber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Expert Rev Clin Immunol 2012; 8: 17-19.
Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2018; 11: Cd006135.
Tan-Lim CSC, Esteban-Ipac NAR, JBV M 3rd et al. Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: a systematic review and network meta-analysis. Pediatr Allergy Immunol 2020; 32: 124-136.
Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev 2012: Cd005205.
Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. Br J Dermatol 2014; 170(Suppl 1): 38-43.
Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol 2019; 33: 2253-2263.
Stalder JF, Bernier C, Ball A et al. Therapeutic patient education in atopic dermatitis: worldwide experiences. Pediatr Dermatol 2013; 30: 329-334.
de Bes J, Legierse CM, Prinsen CA, de Korte J. Patient education in chronic skin diseases: a systematic review. Acta Derm Venereol 2011; 91: 12-17.
Ersser SJ, Cowdell F, Latter S et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2014; 2014: Cd004054.
Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. J Eur Acad Dermatol Venereol 2019; 33: 577-587.
Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2015: Cd007346.
Agency EM. Neoral Soft Gelatin Capsules - Summary of ProductCharacteristics (SmPC) - (emc).
Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314-2324.
Rudikoff D, Cohen SR, Scheinfeld N. Clinical aspects and differential diagnosis of atopic dermatitis. In Rudikoff D, Cohen SR, Scheinfeld N, eds. Atopic Dermatitis and Eczematous Disorders. London: CRC Press, 2014.
Marrs T, Perkin MR, Logan K et al. Bathing frequency is associated with skin barrier dysfunction and atopic dermatitis at three months of age. J Allergy Clin Immunol Pract 2020; 8: 2820-2822.
Ruff SMD, Engebretsen KA, Zachariae C et al. The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis. Br J Dermatol 2018; 178: 879-888.
Kaminski-Hartenthaler A, Meerpohl JJ, Gartlehner G et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Z Evid Fortbild Qual Gesundhwes 2014; 108: 413-420.